Gujarat Kidney and Super Speciality Ltd has announced the price band for its maiden initial public offer (IPO) at Rs. 108 to Rs. 114 per equity share of face value Rs. 2 each.

 

The company’s IPO will open for subscription on Monday, December 22, 2025, and close on Wednesday, December 24, 2025. Investors can bid for a minimum of 128 equity shares, and in multiples of 128 thereafter.

 

Currently, the company has 5,68,43,250 equity shares outstanding, and the IPO is a fresh issue of up to 2,20,00,000 equity shares.

 

One of the regional healthcare players in central Gujarat, the company operates a chain of mid-sized multi-speciality hospitals providing integrated healthcare services, with a focus on secondary and tertiary care. On a consolidated basis, the company runs seven multi-speciality hospitals and four in-hospital pharmacies.

 

The hospitals have a total bed capacity of 490 beds, an approved bed capacity of 445, and an operational capacity of 340 beds.

 

The company provides secondary services (surgical) and tertiary services (super-speciality surgical), along with integrated diagnostic services and pharmacies. It has strategically focused on under-penetrated healthcare markets across four cities in Gujarat, leveraging its understanding of regional patient culture and medical professionals’ mindset to deliver quality and affordable care.

 

Financially, Gujarat Kidney and Super Speciality Ltd reported a revenue of Rs. 40.24 crore and a net profit of Rs. 9.49 crore for the year ending March 31, 2025. For the three months ending June 30, 2025, revenue stood at Rs. 15.26 crore, with a net profit of ₹5.40 crore.

 

Nirbhay Capital Services Private Limited is acting as the book-running lead manager, while MUFG Intime India Limited is the registrar of the offer.

 

The IPO will follow a book-building process, with not more than 75% of the net offer allocated to qualified institutional buyers, and up to 15% and 10% reserved for non-institutional and retail individual bidders, respectively.